Navigation Links
Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies
Date:3/21/2011

KING OF PRUSSIA, Pa., March 21, 2011 /PRNewswire/ -- Data presented by CSL Behring today suggest that treatment with higher dose Hizentra® (IgPro 20) correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies (PI). These data, presented at the 2011 American Academy of Allergy, Asthma and Immunology annual meeting, derived from two recent trials of Hizentra, one performed in the United States and one in the European Union, and aimed to show the relationship between subcutaneous IgG (SCIg) dosage and clinical outcomes. Earlier studies have shown that higher immunoglobulin G (IgG) doses by intravenous (IVIg) infusion result in higher serum IgG and therefore fewer infections.(1, 2) Hizentra is indicated for the treatment of patients with PI.

The study population comprised 46 patients—19 of whom were previously on SCIg—on a dose of 120 milligrams/kilogram body-weight (mg/kg bw) (mean of medians) and 38 patients on a dose of 208.2 mg/kg bw SCIg (mean of medians). Efficacy was assessed over 28 or 54 weeks.

Although both studies demonstrated clear evidence of effectiveness with zero acute serious bacterial infections (aSBIs), patients on the higher of the two doses of SCIg experienced a lower rate of infection (2.76 vs. 5.18 infections/patient/year) and fewer days missed from school/work (2.06 vs. 8.0 days/patient/year). Importantly, the lowest blood level of IgG following a dose increased by 23.8 percent in those patients on the higher dose of SCIg, compared to 8.6 percent in those on the lower dose of SCIg.

"These data suggest that the higher dose of Hizentra provides greater protection from infection and its consequences in patients with primary immunodeficiencies," said Dr. John Hagan, Assistant Professor of Medicine in the Divisions of Allergic Diseases and Primary Immunodeficiencies of the Mayo Clinic in Rochester, MN and lead author of the stu
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months
2. Study of Patients on Chronic Opioid Therapy finds Likely Non-adherent Patients Have Increased Healthcare Costs, More Hospital Days
3. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
4. Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
5. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
6. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
7. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
8. BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies
9. Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and Regeneration
10. DATATRAK Awarded First Study With Kreara Solutions
11. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/27/2014)... , July 27, 2014 /PRNewswire-iReach/ -- ... survey on Global and Chinese Vardenafil (CAS ... basic information of Vardenafil (CAS 224785-90-4) including ... report then explores global and China,s top ... product specification, capacity, production value, cost, gross ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4
... /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ... traded biopharmaceutical company developing human vaccines for diseases ... infectious agents, announced today that Chuck Panozzo, founder ... joined the GeoVax Labs awareness campaign as an ...
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting ... hospital days during the first year after treatment compared ...
Cached Medicine Technology:Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 3Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5
(Date:7/28/2014)... Cuidado Casero , an organization of Medicare certified agencies ... Texas, New Mexico, New Jersey, Virginia, and Puerto Rico, was ... of PAM’s 2014 Gala. , North Texas PAMS is ... Texas chapter was created by a handful of Peruvian physicians ... care for the indigent in Peru. The chapter is developing ...
(Date:7/27/2014)... July 28, 2014 Recently, Wdsshop.de, a reliable ... new collection of fabulous prom dresses on its ... discounted prices, up to 58% off. , “We are pleased ... product line. They are specially created for those who are ... is great and vivid in style. I think our clients ...
(Date:7/27/2014)... provide shorter, more effective treatment options with fewer side ... C, even those most difficult to treat, according to ... Lancet . , Both studies focused on hepatitis C ... the USA, Europe, North Asia, Australia, and South America, ... Around 150 million people worldwide have chronic hepatitis C ...
(Date:7/27/2014)... Ticket Down is a reputable source ... in Inglewood, California on November 15th. This Australian boy band ... to hear songs from this amazing album at the concert. ... California at The Forum will be released for sale to the ... local time TicketDown.com. This popular secondary ticket exchange can also ...
(Date:7/27/2014)... Washington, DC (PRWEB) July 27, 2014 ... off as Latinos demonstrate their passion for protecting our ... community, particularly in the Southwest, will go on hiking ... presentations designed to show their support for permanently protecting ... is about sharing the Latino community’s perspective on the ...
Breaking Medicine News(10 mins):Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3
... 12 As the exclusive official,breaking news service ... 19-22, PR Newswire is featuring profiles of the ... Company: Defibtech, LLC, Booth Number: 16D18-11, ... LLC is a leading innovator in the field ...
... ForHealth Technologies, IntelliFill i.v. robot to ... reduces errors and ... ForHealth Technologies,Inc., a pioneer in medication error reduction and ... its robotic I.V. dose,preparation system, IntelliFill i.v.(TM), by the ...
... BERGEN, N.J., Nov. 12 The Vitamin Shoppe,announced ... Vice President,General Counsel and Corporate Secretary. Mr. Sander ... capacity, Mr. Sander will be responsible for,Legal Affairs, ... "As the Nation,s fastest growing specialty retailer of ...
... First member satisfaction survey shows health improvements, disease ... among valued benefits of plan -, SAN ANTONIO, Nov. ... 91 percent of members of Care Improvement Plus feel,their health ... satisfaction of the plan,s statewide membership. Of those who,feel health ...
... in the November issue of the Springer journal ... has been cut to levels substantially below the cost ... and clinics around the country are likely to discontinue ... to the test and jeopardizing those at risk for ...
... Donostia hospital in representation of Bioef are taking part in ... a portable device that will revolutionise the manner of controlling ... time needed for their detection from the current 24 hours ... to an increase in the number of control points. This ...
Cached Medicine News:Health News:Defibtech, LLC Exhibiting at MEDICA 2008 2Health News:Alegent Health System Automates I.V. Preparation to Enhance Patient Safety 2Health News:The Vitamin Shoppe Names James Sander Vice President, General Counsel and Corporate Secretary 2Health News:Texas Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Osteoporosis care at risk in the United States 2Health News:Design of system that will revolutionize control of influenza epidemics 2
... The Wound Care Manager ... for patient assessment and data ... care. This application was developed ... Wound Care along with the ...
... specifically for the Palm Organizers to ... rounds. It is intended to record ... that are requested by the senior ... round examinations and to record the ...
... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Medicine Products: